Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Endothelial cell-surface adhesion molecules (ECAMs) represent a functional class of transmembrane proteins expressed on the vascular endothelium that facilitate the recruitment and extravasation of circulating blood cells, primarily leukocytes and platelets, into underlying tissues [1.1.1, 1.2.1]. This group includes several distinct families: the immunoglobulin superfamily (e.g., ICAM-1, VCAM-1, and PECAM-1), the selectin family (E-selectin and P-selectin), and junctional adhesion molecules (JAMs) [1.3.1, 1.3.3]. While some members are constitutively expressed at low levels, their expression is significantly upregulated by pro-inflammatory stimuli such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 (IL-1), marking the transition from a quiescent to an activated endothelial state [1.1.2, 1.2.5]. These molecules are essential for the multi-step adhesion cascade, which involves leukocyte rolling (mediated by selectins), firm adhesion (mediated by ICAMs and VCAMs), and transendothelial migration (mediated by PECAM-1 and JAMs) [1.3.1, 1.3.2]. Pathological overexpression of ECAMs is a key driver in chronic inflammatory diseases, atherosclerosis, and the hematogenous metastasis of cancer cells [1.2.1, 1.2.4]. Consequently, they are major therapeutic targets; for example, crizanlizumab is a monoclonal antibody targeting P-selectin used to treat sickle cell disease, and uproleselan is an E-selectin antagonist under investigation for leukemia [1.2.1, 1.3.2]. Soluble forms of these molecules (e.g., sICAM-1, sVCAM-1) are frequently used as clinical biomarkers for endothelial dysfunction and systemic inflammation [1.3.2, 1.3.4].
Inhibition of leukocyte-endothelial cell interactions by blocking the binding of selectins or immunoglobulin-like adhesion molecules to their respective ligands on leukocytes, thereby preventing rolling, adhesion, and transmigration.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Endothelial cell-surface adhesion molecules (ECAMs) (ECAMs).